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Dermatitis herpetiformis (DH) is an inflammatory cutaneous disease with typical histopathological and immunopathological
findings clinically characterized by intensely pruritic polymorphic lesions with a chronic-relapsing course. In addition to classic
clinical manifestations of DH, atypical variants are more and more frequently reported and histological and immunological are
added to them, whereas the impact on quality of life of patients with DH is increasingly important to a certain diagnosis. The
aim of this paper is to describe all the possible clinical, histological, and immunological variants of DH in order to facilitate the
diagnosis of a rare disease and, therefore, little known.
1. Introduction
Dermatitis herpetiformis (DH) is an inflammatory cuta-
neous disease with typical histopathological and immuno-
pathological findings clinically characterized by intensely
pruritic polymorphic lesions with a chronic-relapsing
course, first described by Duhring in 1884 [1]. In 1966,
Marks et al. [2]. reported small-bowel changes in patients
with DH and later gastrointestinal abnormalities described
in patients affected by DH were found to be the same as in
those with celiac disease (CD) [3]. Currently, DH is con-
sidered as the cutaneous manifestation of gluten-dependent
enteropathy, corresponding to CD.
DH is an autoimmune disease, a finding that is strongly
supported by landmark studies revealing the granular depo-
sition of immunoglobulin A (IgA) in the skin [4–6]. The
same type of immunoglobulin was detected in the small
intestinal mucosa of patient affected by CD, even before
the development of the gluten-induced flat jejunal lesions.
This observation on one hand emphasized the pivotal
pathogenetic role of these immune deposits and from the
other side represented a link between the two diseases [7, 8].
2. Clinical Features
The clinical morphology, in particular a polymorphous pre-
sentation and distribution of the lesions, are the hallmarks
of the DH. Primary lesions of DH consist of grouped erythe-
matous papules, urticarial plaques surmounted by vesicles or
also blisters, which may be often replaced by erosions and
excoriations, because of the intense itching characteristically
associated with this condition. Chronic pruritus and excori-
ations might lead to lichenification, furthermore a transient
postinflammatory hyperpigmentation may occur when the
lesion resolve [9–13]. The symmetrical distribution of the
herpetiform lesions on the extensor surfaces of the elbows
(90%), knees (30%), shoulders, middle line of the back,
buttocks, and sacral region is also a typical feature of the
disease. In particular, Cottini [14]. In 1955 first described a
clinical variant with exclusive localization of the lesions on
the knees and elbows symmetrically. Anyway, scalp, nuchal
area, face, and groin may be also involved. No clinical dif-
ferences were described between darker- and white-skinned
individuals, although DH remains primarily a prerogative
of Caucasian population [15]. Most of the patients suffer
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not only itching but also tickle or burning sensation even
before the onset of the skin lesions.
An uncommon skin manifestation of DH is represented
by purpuric lesions occasionally described on palmo-plantar
surfaces of children, but rarely reported in adults. First
descriptions of DH presenting as purpuric, erythematous,
or hemorrhagic palmar or plantar lesions date from 1971
[16, 17]. Fraser et al. reported such lesions in four of 14
patients with DH [17]. In 1979, Katz and Marks noted that
vesicles may be hemorrhagic, particularly if they are located
on the hands [18]. Moulin et al. [19] eventually described
reported four DH patients with palmar “pseudopurpuric
lesions” which showed typical histologic changes of DH
in three out of four cases. Pierce et al. [20] described a
27-year-old man with typical DH and additional purpuric
lesions on the palms. In 1986, 47 pediatric series of 47 DH
cases by Karpati et al. [21], 30 (64%) showed red-brown
palmar purpuric lesions, which, however, were not biopsied.
Sometimes, petechial lesions on the fingertips may be the
only symptom of DH, as reported by Moulin et al. [19],
Rutten and Goos [22], Hofmann et al. [23], and recently
Flann et al. [24]. Finally, the last case was described in 2011
by Heinlin et al. [25]. In a 15-year-old female with a 6-month
history of recurrent painful petechiae on the fingers and feet,
that was diagnosed as DH after histopathology, direct- and
indirect- immunofluorescence (DIF, IIF).
However, atypical clinical presentation of DH reported in
the literature includes also palmoplantar keratosis, wheals of
chronic urticaria and lesions mimicking prurigo pigmentosa
[26–28]. In particular, Ohshima et al. [26] in 2003 described
a 63-year-old Japanese man which presented palmoplantar
keratosis, in addition to itchy areas of erythema on the
buttocks and knees with small blisters on the border that
were clinically, histologically, and immunologically compat-
ible with DH. The histologic evaluation of palmoplantar
keratotic lesions showed hyperkeratosis, acanthosis, and
cellular infiltration, mainly of lymphocytes, in the dermal
papillae, aspects that were more compatible with psoriasis,
but DIF showed granular IgA deposits in the dermal papillae
confirming the diagnosis of DH. An unusual clinical presen-
tation of DH in children described instead by Powell et al.
[27] in 2004 consisted of chronic urticaria-like skin lesions.
Histologic evaluation showed neutrophilic microabscesses
in the dermal papilla with subepidermal blister formation,
suggestive of DH, that was confirmed by fibrillar IgA
deposition along the basement membrane zone (BMZ) with
papillary accentuation revealed by DIF. Finally, Saito et al.
[28] in 2005 described another atypical clinical presentation
of DH, that was also in a Japanese subject, with features of
prurigo pigmentosa but characterized by both histological
and immunological aspect of DH.
3. Histopathology
The classic histopathologic features of DH seen on light
microscopy include a subepidermal cleft with neutrophils,
that are considered the most likely responsible for the
dermal-epidermal separation [29], and a few eosinophils
at the tips of dermal papillae, that are often accompanied
by a perivascular mixed inflammatory infiltrate [12, 26].
While these findings are characteristic, there are a number
of patients who present with pruritic, excoriated skin lesions
with clinical and immunological features of DH in whom
the histologic findings are nonspecific and do not confirm
the diagnosis as showed by Warren and Cockerell [30],
which found that 37.5% of DH patients had hematoxylin
and eosin findings of a lymphocytic infiltrate only with
fibrosis in the dermal papillae and ectatic capillaries. The
authors hypothesized that the nonspecific histologic findings
could represent both a sampling error on the part of the
clinician taking the biopsy, in particular, choosing excoriated
lesions that correspond to a later stage of the disease, or the
pathology laboratory in sampling the lesion for histology,
considering appropriate a progressive cutting of the tissue
block, or distinct subgroup of dermatitis herpetiformis,
possibly with a separate antigenic target [30].
4. DIF
Actually DIF of uninvolved skin collected in the perilesional
site is considered as the diagnostic gold standard for DH [12].
The choice of normal appearing perilesional skin as site of
biopsy specimen for DIF is not random, because in this site
DH patients showed greater IgA deposition than in nonle-
sional or lesional skin as demonstrated by Zone et al. [4].
Two different patterns are possible: (a) granular deposits
in the dermal papillae and (b) granular deposits along the
basement membrane. In both cases, deposits are thought to
be polyclonal but are mainly composed of IgA1 [31]. The two
patterns may also be present as a combination resulting in
granular IgA deposition along the basement membrane with
accentuation at the tips of the dermal papillae [9–11, 32]. A
third different pattern, presents in 50% of Japanese popula-
tions, first described in 1993 by Kawana and Segawa [33] as
“fibrillar pattern,” was subsequently reconsidered by Ko et al.
[34] in 2010. The fundamental difference between this last
and previous is that the IgA deposition presents as linear
streaks rather than fine granules in the papillary dermis. As
suggested by Ko et al., the fibrillar pattern of IgA deposition
may correlate with a clinical variant of DH or another as
yet undefined disorder, and some case reports of atypical
clinical presentations, that may be urticarial or psoriasiform,
support this hypothesis [35, 36]. The correlation between
the fibrillar DIF pattern and DH is, however, still debated.
Although often the granular and the fibrillar patterns are
associated in patients with DH, the last one alone more often
correlates with atypical features, including atypical clinical
presentations, absence of HLA-B8/DR3DQ2 haplotype, and
lack of gluten-sensitive enteropathy or detectable circulating
autoantibodies [37]. However, not all authors agree that,
considering that the two different pattern may be the
expression of a different method of sectioning [33].
5. Serologic Findings
Serologic testing is a useful adjunct to tissue-based studies.
Contrary to the other bullous disorders, DH patients have
no circulating autoantibodies binding to the cutaneous
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basementmembrane components or to other adherent struc-
tures of the skin, but they have gluten-induced IgA autoanti-
bodies against transglutaminase (TG) 2 and TG3 also called
tissue-TG (t-TG) and epidermal-TG (e-TG), respectively
[13].
TG represents an evolutionary conserved family of Ca+2-
dependent enzymes that covalently cross-link or modify pro-
teins by formation of an isopeptide bond between a peptide-
bound glutamine residue and a primary amine, most
commonly a lysine residue either within the same or a neigh-
boring polypeptide chain [38]. Nine human types of TGwere
identified and some of them are expressed in the epidermis.
TG2, among them, is the best characterized and also the
most abundant and widely distributed [39]. Over time,
different authors demonstrated that the enzymatic activity of
TG2 is implicated in several diseases as Huntington disease,
Alzheimer disease, and CD [40–42]. In particular, CD TG2
catalyzes highly specific deamidation of gluten peptides
improving the binding of the peptides to the disease-
associated HLA DQ2 and DQ8 molecules and becoming
essential for the T-cell-mediated immune response against
gluten. TG2 is also the primary autoantigen of CD recognized
by autoantibodies of IgA1 class. These autoantibodies are
considered the main serological marker of CD as disease-
specific and more generally of gluten-sensitivity diseases and
therefore of DH [12, 38, 43]. Levels of anti-TG2 correlate
with bowel damage and gluten-free diet adherence in
DH/CD patients and are measured using an enzyme-linked
immunosorbent assay (ELISA) [44]. In DH, some authors
have demonstrated an IgA anti-tTG specificity higher than
90%, and a sensitivity ranging from 47% to 95% [45–49].
However, as demonstrated by Sa´rdy et al. [50] the target
autoantigen of DH is represented by TG3, that shares a
64% of homology with TG2 and overlapping sensitivity and
specificity. As recently demonstrated by Stamnaes et al. [39]
is also able to accommodate gluten peptides as substrates and
form either thioester or isopeptide-linked complexes with
these peptides stimulating the immune system’s response,
even if it is still unclear how it gets to the skin lesions.
Although promising, the anti-eTG assay has not yet been
approved in the United States for in vitro use to diagnose DH
[51].
In addition to anti-TG2 antibodies, also those anti-EMA
have become relatively sensitive and specific tools for initial
detection of gluten-sensitive disease and, therefore, of DH. In
particular, anti-EMA antibodies belong to the IgA1 subclass
and are directed against primate smooth muscle reticular
connective tissue. The detection of EMA is based on an
indirect immunofluorescence assay on monkey oesophagus
and it is more time-consuming and operator-dependent than
the one of anti-TG2 ELISA testing [52], showing a specificity
close to 100%, and a sensitivity ranging from 52% to 100%
for the diagnosis of DH [44–47, 53].
Other autoantibodies are shared between DH and CD
such as antigliadin antibodies and antireticulin antibodies,
without, however, the same diagnostic value of anti-TG2 and
anti-EMA.
In 2006, Sugai et al. first showed that the most reliable
diagnostic test to identify gluten sensitivity in DH patients
was the detection of antibodies against deamidated synthetic
gliadin-derived peptides, both IgA and IgG isotypes [54].
Recently, a new CD serum marker based on TG2 covalently
cross-linked to deamidated gliadin peptides, coined “neo-
epitope,” was carefully studied by Matthias et al. and data
supporting the use of this new assay (AESKULISA CeliCheck
New Generation) in CD diagnosis were obtained in a
longitudinal study of 2684 eligible subjects demonstrating
a sensitivity of 92,31% and a specificity of 82,89%, that
were highest when compared to TG2 ELISA test or anti-
EMA tests [55]. The diagnostic value of these antibodies was
also confirmed by Jaskowski et al. [56], which demonstrated
the superior sensitivity of anti-tTG/DGP EIA screen (IgA +
IgG) compared to IgA anti-tTG both in pediatric CD (92,6%
versus 90,7%) and adult DH (65% versus 48,8% and 62%
versus 44% in retrospective and prospective sera, resp.).
Furthermore, very recently, Kasperkiewicz et al. [57] showed
the higher sensitivity of the anti-GAF3X ELISA, a novel CD
serologic assay using deamidated gliadin-analogous fusion
peptides, to detect CD-associated autoantibodies in patients
with DH compared with tests using native gliadin, tTG or
endomysium as substrates.
6. Conclusion
From the data reported above, it seems evident that the
diagnosis of DH can be difficult and, therefore, requires
a complex approach, that should be clinical, histological
and immunological, having regards to the atypical variants
more and more frequently described in the literature. This
becomes crucial since, as it is known, patients with DH
present a significant reduction in their quality of life, mainly
due to the need of a lifelong gluten-free diet and, conse-
quently, to a significant change in lifestyle and eating habits.
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